Novel small molecule drug KVX-053 for targeting PTP4A3 in asthma and allergy
Introducing KVX-053, a groundbreaking small molecule drug targeting PTP4A3, designed to reduce inflammation and heal lung injury in asthma and allergy patients. Currently in IND-enabling studies, KVX-053 has shown effectiveness in the lower respiratory tract and is now being tested for the upper tract.
Overview
KVX-053 is a pioneering small molecule drug developed to target PTP4A3, a regulatory protein involved in inflammation and cytokine release, which are critical in various lung disorders. This drug has shown preclinical efficacy in reducing inflammation, lung injury, and cellular infiltration in the lower respiratory tract. With its potential to prevent and heal lung injuries, KVX-053 is now being evaluated for its effects on the upper respiratory tract, offering a promising solution for asthma and allergy treatments.
Technical specifications
- Mechanism of Action: KVX-053 targets PTP4A3, reducing proinflammatory cytokine release and inflammatory signaling.
- Applications: Effective in treating lung injuries caused by chemicals, viral infections, gastric aspiration, and mechanical ventilation.
- Preclinical Evidence: Demonstrated in vivo success in ameliorating lung injury and inflammation in lower respiratory tract models.
- Future Testing: Planned evaluation in upper respiratory tract using non-invasive delivery systems, similar to existing allergy medications.
Technology readiness level
KVX-053 is currently at TRL 3, with ongoing IND-enabling studies and plans for further validation in vivo using standardized allergy/asthma models.
About KeViRx, Inc.
KeViRx, Inc. is a Charlottesville, Virginia-based biotechnology company founded in 2016 that focuses on the development of small molecule therapeutics for treating microvascular leakage and inflammation. The company's platform technology, centered on its lead asset KVX-053, is designed to heal the endothelial lining within blood vessels and regenerate lung cell connections. Unlike conventional treatments that target specific pathogens, KeViRx’s approach is host-directed, aiming to address the underlying cellular damage that contributes to acute lung injury, which can be caused by viral infections, sepsis, bacterial pneumonia, or chemical inhalation.
This technology is critical for patients in intensive care settings who may otherwise rely on mechanical ventilation, which can exacerbate lung damage. By repairing the root causes of inflammation and restoring lung function, KVX-053 aims to improve patient recovery and reduce reliance on invasive respiratory support. The company’s research has shown efficacy in various preclinical models of lung injury and cancer. Supported by non-dilutive funding, including grants from the U.S. Department of Defense and membership in the Blue Knight collaboration, KeViRx is actively advancing its lead compound toward clinical trials.
Inquire about this partnering listing
Industry applications
delivered to your inbox.